HC Wainwright Reaffirms “Buy” Rating for Coya Therapeutics (NASDAQ:COYA)

HC Wainwright reiterated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a research report released on Monday,Benzinga reports. The brokerage currently has a $18.00 price target on the stock. HC Wainwright also issued estimates for Coya Therapeutics’ Q4 2024 earnings at ($0.32) EPS, FY2024 earnings at ($1.13) EPS, Q1 2025 earnings at ($0.44) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.50) EPS, Q4 2025 earnings at ($0.52) EPS and FY2025 earnings at ($1.68) EPS.

Separately, Chardan Capital restated a “buy” rating and set a $14.00 price objective on shares of Coya Therapeutics in a research report on Thursday, November 7th.

Coya Therapeutics Price Performance

Shares of Coya Therapeutics stock opened at $6.81 on Monday. The stock’s 50 day simple moving average is $7.11 and its 200-day simple moving average is $7.01. The stock has a market cap of $113.80 million, a P/E ratio of -10.48 and a beta of 0.46. Coya Therapeutics has a 1-year low of $4.75 and a 1-year high of $10.69.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.15. As a group, research analysts expect that Coya Therapeutics will post -1.27 EPS for the current fiscal year.

Insider Buying and Selling at Coya Therapeutics

In related news, CEO Arun Swaminathan purchased 5,000 shares of the company’s stock in a transaction on Monday, November 11th. The stock was acquired at an average cost of $7.34 per share, for a total transaction of $36,700.00. Following the completion of the transaction, the chief executive officer now directly owns 5,000 shares in the company, valued at approximately $36,700. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Insiders have acquired 9,510 shares of company stock worth $69,615 over the last quarter. 12.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Coya Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in Coya Therapeutics by 772.3% during the first quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock worth $8,407,000 after purchasing an additional 750,338 shares in the last quarter. Gilbert & Cook Inc. acquired a new position in Coya Therapeutics during the 2nd quarter worth about $61,000. Renaissance Technologies LLC purchased a new position in Coya Therapeutics during the 2nd quarter valued at about $101,000. Finally, GHP Investment Advisors Inc. acquired a new position in Coya Therapeutics in the 3rd quarter valued at about $169,000. Hedge funds and other institutional investors own 39.75% of the company’s stock.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.